Tratamento da migranea refratária na unidade de emergência do complexo hospitalar de barbacena – rede FHEMIG
Keywords:
Holoperidol, Cefaleia, RefratoryAbstract
Headache is one of the primary neurological complaints in emergency departments. It is not uncommon for headaches to persist even with appropriate treatment. The initial evaluation should differentiate between primary and secondary headaches, determine the need for further investigation, and treat the acute pain. Migraines, in particular, are among the most disabling primary headches, affecting quality of life and burdening the healthcare system. Refractory migraine is characterized by the lack of response to standard preventive and acute treatment, requiring a more aggressive therapeutic approach.
The objective of the study is to evaluate the therapeutic response in the treatment of refractory migraine at the Emergency Department of the Barbacena Hospital Complex, two hours after the administration of a combination of 5 mg of intravenous or oral haloperidol and intravenous or oral dexamethasone in patients classified as refractory to initial treatment.
The study was conducted as a prospective observational study with patients considered refractory to initial migraine treatment. Patients who did not respond to at least three adequate dose medications were included. After obtaining consent, demographic data and medical histories were collected, and patients completed the Visual Analog Scale (VAS) to quantify pain. They received 5 mg of haloperidol (oral or intravenous) and 4 mg of dexamethasone (oral or intravenous). After two hours, pain intensity was reassessed and quantified.
The study is ongoing, with data collection from August 1, 2023, to July 31, 2024. However, with the end approaching, it is now possible to evaluate the results and clarify the proposed objective. Currently, there are 16 patients, 15 females and 1 male, with an average age of 28 years. The results are favorable, showing improvement after therapy by at least 2 points on the VAS and a maximum of 10 points, with only one result indifferent to the treatment.
The combination of haloperidol and dexamethasone appears promising in treating patients who do not respond to conventional therapy, providing significant pain relief. This approach can reduce patient morbidity and healthcare costs. Additional studies are needed to optimize the doses and combinations of these medications to maximize efficacy and minimize risks.
Downloads
References
Referências Bibliográficas
Robblee Jennifer, W. Grimsrud Kate. Emergency Department and Inpatient Management of Headache in Adults. Current Neurology and Neuroscience Reports. 2020; 20: 7.
Minen MT, Tanev K, Friedman BW. Evaluation and treatment of migraine in the emergency department: a review. Headache. 2014 Jul-Aug;54(7):1131-45.
Silva, A. V. da ., Kiy, L. M. C., Alves, C. de A., Kirylko, G. C., Bello, V. A., & Poli-Frederico, R. C.. (2021). Impact of headache on a supplemental healthcare emergency unit and on use of opioids. Arquivos De Neuro-psiquiatria, 79(7), 579–583.
Benevides ML, Oliveira S de S, Aguilar-Nascimento JE. A associação de haloperidol, dexametasona e ondansetrona reduz a intensidade de náusea, dor e consumo de morfina após gastrectomia vertical laparoscópica. Rev Bras Anestesiol [Internet]. 2013Sep;63(5):404-9.
Santos PSF, Melhado EM, Kaup AO, Costa ATNMD, Roesler CAP, Piovesan ÉJ, Sarmento EM, Theotonio GOM, Campos HC, Fortini I, Souza JA, Júnior JAM, Segundo JBA, Carvalho JJF, Speziali JG, Calia LC, Barea LM, Queiroz LP, Souza MNP, Figueiredo MRCF, Costa MENM, Peres MFP, Jurno ME, Peixoto PM, Kowacs PA, Rocha-Filho PAS, Filho PFM, Silva-Neto RP, Fragoso YD. Consensus of the Brazilian Headache Society (SBCe) for prophylactic treatment of episodic migraine: part II. Arq Neuropsiquiatr. 2022 Sep;80(9):953-969.
Kabbouche Marielle; K. Khoury ChaoukiK. Management of Primary Headacheinthe Emergency Department and Inpatient Headache Unit. Semin Pediatr Neurol, 2016. Elsevier Inc. 23:40-43 C.
Headache Classification Committee of the International Headache Society (IHS). (2018). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018; 38(1), 1-211.
Monzillo Paulo H et al. Tratamento agudo da crise de enxaqueca refratária na emergência. Arq Neuropsiquiatria. 2004; 62(2-B):513-518.
Steiner T. J, Birbeck G. L, Jensen R. H, Katsarava Z, Martelletti P, & Stovner L. J. The Global Campaign, World Health Organization and Lifting The Burden: collaboration in action. The Journal of Headache and Pain. 2013; 14(1), 13.
Schwedt TJ, Matharu MS, Dodick DW. Thunderclap headache. Lancet Neurol. 2006 Jul;5(7):621-31.
Nye BL, Ward TN. Clinic and emergency room evaluation and testing of headache. Headache. 2015;55(9):1301–8 A great review article from 2015 on emergency department management of headache.
Dodick DW. Pearls: headache. Semin Neurol. 2010;30(1):74–81.
Kowacs F, Roesler CAP, Silva-Néto RP. "Migrânea" e "enxaqueca": palavras não contrapostas, mas complementares ["Migrânea" and "enxaqueca": not opposite, but complementary words]. Arq Neuropsiquiatr. 2021 Mar;79(3):248-250. Portuguese.
Charles A. The pathophysiology of migraine: implications for clinical management. Lancet Neurol. 2018; Feb;17(2): 174-182.
Ferreira, K. dos S., Bolinelli, L. P., & Pagotto, L. C.. (2015). Migraine and menstrual cycle synchrony in females: is there a relationship? Case report. Revista Dor, 16(2), 156–158.
Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of Migraine: A Disorder of Sensory Processing. Physiol Rev. 2017; Apr;97(2): 553-622.
Noseda R, Burstein R. Migraine pathophysiology: anatomy of the trigeminovascular pathway and associated neurological symptoms, cortical spreading depression, sensitization, and modulation of pain. Pain. 2013; Dec;154 Suppl 1:S44-53.
Vos T, Abajobir A. A, Abate K. H, Abbafati C, Abbas K. M, Abd-Allah F & Aboyans, V. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet. 2016; 390. 1211-1259.
Amy A. Gelfand, and Peter J. Goadsby, MD, PhD2. A Neurologist’s Guide to Acute Migraine Therapy in the Emergency Room. The Neurohospitalist. 2012; 2(2) 51-59.
Sacco Simona et al. European headache federation consensus on the definition of resistant and refractory Migraine. The Journal of Headache and Pain. 2020; 21:76.
MARTINS, Isabel Pavão; SOUSA, Lívia; MONTEIRO, J M Pereira. Enxaqueca crônica, refratária e cefaleias por uso excessivo de medicamentos: Revisão clínica e terapêutica. Sinapse - Sociedade Portuguesa de Neurologia. vol.18 nº1, 2018
Bigal ME, Bordini CA, Speciali JG. Intravenous chlorpromazine in the emergency department treatment of migraines: a randomized controlled trial. J Emerg Med. 2002 Aug;23(2):141-8. doi: 10.1016/s0736-4679(02)00502-4. PMID: 12359281.
Honkaniemi J, Liimatainen S, Rainesalo S, Sulavuori S. Haloperidol in the acute treatment of migraine: a randomized, double-blind, placebo-controlled study. Headache. 2006 May;46(5):781-7.
Woldeamanuel YW, Rapoport AM, Cowan RP. The place of corticosteroids in migraine attack management: A 65-year systematic review with pooled analysis and critical appraisal. Cephalalgia. 2015 Oct;35(11):996-1024.
American College of Emergency Physicians Clinical Policies Subcommittee (Writing Committee) on Acute Headache:; Godwin SA, Cherkas DS, Panagos PD, Shih RD, Byyny R, Wolf SJ. Clinical Policy: Critical Issues in the Evaluation and Management of Adult Patients Presenting to the Emergency Department With Acute Headache. Ann Emerg Med. 2019 Oct;74(4):e41-e74.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Sara Luiza Ronzani da Cunha, Mauro Eduardo Jurno, Priscilla Garcia de Andrade (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
